Kidney and Pancreas Transplant Clinical Trials

California Pacific CURRENTS: The online journal of CPMC Research Institute

Below is a listing of kidney and liver transplant clinical trials  approved by CPMC’s Institutional Review Board:

 

Natural History of Infection Caused by BK Virus (and Other Opportunistic Viral Pathogens) in Renal Transplant Recipients

Description: The purpose of this study is to characterize the natural history of BK viremia

Investigators

Eligibility Requirements

Subjects, 18 years and older, who received a renal or renal-pancreas transplant at risk for BK virus infection

Status

Active and open to enrollment

Contacts

Serena Lai, 415-600-1744

 

Evaluation of the Benefits and Risks in Maintenance Renal Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based Immunosuppression

Description: The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-36 months after kidney transplant

Investigators

Eligibility Requirements

Subject between 18 and 75 years old who are recipients of a renal allograft from a living donor or a deceased donor between 6-36 months prior to enrollment

Status

Active and open to enrollment

Contacts

Serena Lai, 415-600-1744

 

Evaluation of Acute Rejection Rates in de Novo Renal Transplant Recipients Following Thymoglobulin Induction, CNI-free, Nulojix (Belatacept)-Based Immunosuppression

Description: A 2 year study evaluating the efficacy of the combination of Thymoglobulin induction, belatacept, everolimus and corticosteroid withdrawal vs standard of care in preventing acute rejection in adult kidney transplant recipients

Investigators

Eligibility Requirements

Subjects 18 years and older with end stage renal disease scheduled to undergo a living or deceased donor renal transplant

Status

Active and open to enrollment

Contacts

Lisa Takemori, 415-600-1627

 

A Randomized, Placebo-controlled, Prospective, Double-blind, Multicenter Phase 2/3 Study of the Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Recipients of a Donation After Brain Death Kidney Transplant

Description: A two part study evaluating if SANGUINATE can be used to prevent delayed graft function following renal transplantation

Investigators

Eligibility Requirements

Subjects, 18 years and older, with dialysis dependent renal failure who are about to receive a first kidney transplant from a deceased donor with a DGF risk score using the Irish scale of ≥ 25%

Status

Active and open to enrollment

Contacts

Serena Lai, 415-600-1744

 

A Prospective Observational Trial to Evaluate the Correlation of T-SPOT® Response to CMV Infection and T Cell-mediated Acute Graft Rejection

Description: A non-interventional study evaluating the utility of T-SPOT assays to monitor T cell immune response to CMV and donor antigens

Investigators

Eligibility Requirements

Kidney transplant recipients 18 y/o and older who are CMV seronegative who receive a kidney from a CMV seropositive donor and are within 6 months of their transplant surgery

Status

Active and open to enrollment

Contacts

Lisa Takemori, 415-600-1627

 

A Phase 3, Randomized, Double-blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of QPI-1002 for Prevention of Delayed Graft Function in Recipients of a Donation After Brain Death Older Donor Kidney Transplant

Description: A 1 year study evaluating if QPI-1002 can be used to prevent delayed graft function in recipients of an older donor kidneys

Investigators

Eligibility Requirements

Subjects, 18 years and older, with dialysis dependent renal failure (at least 2 months prior to transplantation) who are about to receive a kidney transplant from a deceased donor ≥ 45 years of age

Status

Active and open to enrollment

Contacts

Serena Lai, 415-600-1744